BG Medicine, Inc. BG Medicine, Inc.

BG Medicine, Inc.

BGMD

Rank in Stocks #34940
BG Medicine, Inc. is dedicated to the development and commercialization of... BG Medicine, Inc. is dedicated to the development and commercialization of diagnostic products aimed at guiding patient care for individuals in the United States afflicted with heart failure and related conditions. Its product portfolio includes the BGM Galectin-3 Test, an in vitro diagnostic solution that quantifies galectin-3 levels in blood serum or plasma using an enzyme-linked immunosorbent assay (ELISA) on a microtiter plate platform. Additionally, the company provides the CardioSCORE Test, a multi-analyte, biomarker-based blood test designed to assess the short-term risk of atherothrombotic cardiovascular events, such as myocardial infarction (heart attack) and ischemic stroke. BG Medicine maintains licensing, development, and commercialization agreements with major partners like Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc., specifically for automated versions of its galectin-3 test. Furthermore, it has forged a strategic alliance with Abbott Laboratories to jointly develop and market galectin-3 assay kits, along with their corresponding control kits and calibrators. Founded in 2000, the company was initially known as Beyond Genomics, Inc., before rebranding to BG Medicine, Inc. in October 2004. Its corporate headquarters are located in Waltham, Massachusetts.
Share Price
$0.0001
Last synced: 2026-11-10
Market Cap
$1.13K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country

Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this

Category

Healthcare
Operating Margin for BG Medicine, Inc. (BGMD)
Operating Margin as of November 2026 TTM: -295.66%
According to BG Medicine, Inc.'s latest financial reports, its current operating margin (TTM) is -295.66%. At the end of 2015 the company had an operating margin of -295.66%.
Operating Margin history for BG Medicine, Inc. from 2004 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -295.66% 0.00%
2015 -295.66% 11.92%
2014 -264.16% -25.15%
2013 -352.91% -56.29%
2012 -807.39% -24.55%
2011 -1,070.07% -40.00%
2010 -1,783.39% 847.00%
2009 -188.32% 159.64%
2008 -72.53% 4.60%
2006 -69.34% -86.21%
2005 -502.87% 48.37%
2004 -338.93% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
28.37% -100.10%
US
12.36% -100.04%
FR
11.78% -100.04%
US
31.11% -100.11%
JP
10.21% -100.03%
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about BG Medicine, Inc.'s operating margin

What is BG Medicine, Inc.'s operating margin?

BG Medicine, Inc.'s operating margin is -295.66%, as of Nov 2026.

What was BG Medicine, Inc.'s operating margin in 2015?

In 2015, BG Medicine, Inc.'s operating margin was -295.66%, compared with -264.16% in 2014.

How has BG Medicine, Inc.'s operating margin changed since 2010?

From 2010 to 2015, BG Medicine, Inc.'s operating margin was highest in 2014 (-264.16%) and lowest in 2010 (-1,783.39%).

How does BG Medicine, Inc.'s operating margin compare with similar companies?

BG Medicine, Inc.'s operating margin (-295.66%) is lower than that of all 5 similar companies listed above. The highest among them is HOYA Corporation, with 31.11%.